Mann Christopher D, Neal Christopher P, Garcea Giuseppe, Manson Margaret M, Dennison Ashley R, Berry David P
Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, Biocentre, University of Leicester, Leicester, UK.
Eur J Cancer Prev. 2009 Feb;18(1):13-25. doi: 10.1097/CEJ.0b013e3282f0c090.
Hepatocellular carcinoma (HCC) is the fifth commonest malignancy worldwide and the incidence is rising. Surgery, including transplantation resection, is currently the most effective treatment for HCC; however, recurrence rates are high and long-term survival is poor. Identifying novel chemopreventive and chemotherapeutic agents and targeting them to patients at high risk of developing HCC or following curative treatment may go some way towards improving prognosis. This review examines current knowledge regarding the chemopreventive and chemotherapeutic potential of phytochemicals in heptocarcinogenesis. Both in-vitro and animal studies demonstrate that several phytochemicals, including curcumin, resveratrol, green tea catechins, oltipraz and silibinin, possess promising chemopreventive and chemotherapeutic properties. Despite this, very few clinical trials have been performed. Problems regarding validation of biomarkers, agent delivery, side effects and patient selection are barriers that need to be overcome to determine the potential of such agents in clinical practice.
肝细胞癌(HCC)是全球第五大常见恶性肿瘤,且发病率呈上升趋势。手术,包括移植切除,是目前治疗HCC最有效的方法;然而,复发率高且长期生存率低。识别新型化学预防和化疗药物,并将其应用于有发生HCC高风险的患者或根治性治疗后的患者,可能在一定程度上改善预后。本综述探讨了目前关于植物化学物质在肝癌发生中的化学预防和化疗潜力的知识。体外和动物研究均表明,几种植物化学物质,包括姜黄素、白藜芦醇、绿茶儿茶素、奥替普拉和水飞蓟宾,具有有前景的化学预防和化疗特性。尽管如此,进行的临床试验却很少。生物标志物验证、药物递送、副作用和患者选择等问题是确定此类药物在临床实践中的潜力需要克服的障碍。